Sugi Predict

Sugi Predict / Compounds / SCHEMBL1998487

SCHEMBL1998487

SCHEMBL1998487

O=CNc1cnc2ccccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 1/20 0.56
▸ PDGFRA P16234 1/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ HSP90AA1 P07900 1/20 0.56
▸ HSP90AB1 P08238 1/20 0.56
▸ ALDH1A1 P00352 3/20 0.51
▸ POLB P06746 1/20 0.51
▸ GAA P10253 1/20 0.51
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ LMNA P02545 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ HPGD P15428 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ PDE10A Q9Y233 2/20 0.44
▸ RHOA P61586 3/20 0.43
▸ KMT2A Q03164 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27737552 0.79 HSD11B1 (0.46) PDGFRBPDGFRAKDM4EHSP90AA1HSP90AB1
SCHEMBL1857789 0.79 PDGFRB (0.56) PDGFRBPDGFRAKDM4EHSP90AA1HSP90AB1
Hydrochloric Acid SCHEMBL28301820 0.78 HSD11B1 (0.45) PDGFRBPDGFRAKDM4EHSP90AA1HSP90AB1
SCHEMBL5780177 0.77 PDGFRB (0.62) PDGFRBPDGFRAKDM4EHSP90AA1HSP90AB1
SCHEMBL213933 0.76 NCF1 (0.59) KDM4ENPC1RAB9AHPGDHSD17B10
SCHEMBL3815563 0.75 PDGFRB (0.60) PDGFRBPDGFRAKDM4EHSP90AA1HSP90AB1
SCHEMBL7099643 0.75 PDGFRB (0.60) PDGFRBPDGFRAKDM4EHSP90AA1HSP90AB1
SCHEMBL28693008 0.75 PDGFRB (0.60) PDGFRBPDGFRAKDM4EHSP90AA1HSP90AB1
Hydrochloric Acid SCHEMBL27836524 0.74 NCF1 (0.57) KDM4ENPC1RAB9AHPGDHSD17B10
SCHEMBL1998485 0.74 PDGFRB (0.55) PDGFRBPDGFRAKDM4EHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110698418-B 3-arylamino quinoxaline-2-formamide derivative and preparation method and application thereof 广西师范大学 2022-07-01 — — CN claimed
CN-110698418-A 3-arylamino quinoxaline-2-formamide derivative and preparation method and application thereof 广西师范大学 2020-01-17 — — CN claimed
CN-108601840-A Combination therapy of PD-1 signaling inhibitors 国立大学法人京都大学 2018-09-28 — — CN claimed
CN-105073738-B Quinoline and quinoxaline amide-type as sodium channel modulators 沃泰克斯药物股份有限公司 2018-01-05 — — CN claimed
CN-107108534-A Probes for Imaging Huntingtin CHDI基金会股份有限公司 2017-08-29 — — CN claimed
WO-2012103520-A1 METHODS AND COMPOSITIONS FOR MODULATING CYCLOPHILIN D BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2012-08-02 — — WO claimed
CN-110698418-B 3-arylamino quinoxaline-2-formamide derivative and preparation method and application thereof 广西师范大学 2022-07-01 — — CN disclosed
CN-110981819-B Quinoxaline signal channel inhibitor and preparation method and application thereof 广西师范大学 2022-07-01 — — CN disclosed
CN-110981819-A Quinoxaline signal channel inhibitor and preparation method and application thereof 广西师范大学 2020-04-10 — — CN disclosed
CN-110698418-A 3-arylamino quinoxaline-2-formamide derivative and preparation method and application thereof 广西师范大学 2020-01-17 — — CN disclosed
CN-110234401-A METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION 德克萨斯大学系统董事会 2019-09-13 — — CN disclosed
CN-105473554-B Condensed piperidine amide as ion channel modulators 沃泰克斯药物股份有限公司 2019-08-13 — — CN disclosed
CN-109689656-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2019-04-26 — — CN disclosed
EP-1795527-B1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMA CO LTD (JP) 2009-04-22 — — EP disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 — — US disclosed
EP-1953165-A1 AZA-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-08-06 — — EP disclosed
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative MSD K.K. (JP) 2008-07-17 — — US disclosed
EP-1795527-A1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-13 — — EP disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 — — EP disclosed
US-6875743-B1 Cell adhesion inhibitors BIOGEN, INC. (US) 2005-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 PDGFRB 1726/4885PDGFRA 842/4885KDM4E 3385/4885
US-20080171753-A1 Carbamoyl-Substituted Spiro Derivative HRH3, HRH4, HRH2 PDGFRB 635/4885PDGFRA 469/4885KDM4E 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.